Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6926496 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Cohort 2 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Cohort 3 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Cohort 4 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Cohort 5 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Cohort 6 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Matching placebo to RO6926496 |
| RO6926496 | DRUG | single, ascending dose, intravenous administration |
Inclusion Criteria: * Healthy male participants, 18 to 45 years of age; healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history * A body mass index between 18 and 30 kg/m2 * Male subjects and their partners of childbearing ...
RO6926496 is an investigational small molecule being developed by Roche Holding AG (RHHBY). It is currently in Phase 1 clinical development. The drug has been studied in a completed clinical trial involving healthy volunteers, with a total enrollment of 48 participants.
RO6926496 is being studied for use in healthy volunteers. The completed Phase 1 trial was designed to evaluate the drug in this population. Its potential therapeutic application has not been established, as it is still in early-stage clinical development.
RO6926496 is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the clinical trial for this investigational small molecule. The drug is currently in Phase 1 development.
RO6926496 is in Phase 1 clinical development. The drug has completed one Phase 1 trial in healthy volunteers. It is an investigational agent and has not been approved for any use. Further clinical development status is not specified.
RO6926496 has been studied in one completed clinical trial, NCT02281786, titled "A Study of RO6926496 in Healthy Volunteers." This Phase 1 trial enrolled 48 healthy male participants aged 18 years and older in the United Kingdom. The trial was randomized, double-blind, and controlled.
RO6926496 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug has completed a Phase 1 trial in healthy volunteers, but no approval status has been established. It remains under investigation by Roche Holding AG.